Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 PDE4 Supports its Potential to Treat Autoimmune and Inflammatory Diseases; Company Invited to Present at Upcoming Crohns & Colitis Foundation Conference

BEVERLY Mass. Oct. 12 2018 GLOBE NEWSWIRE Innovation Pharmaceuticals OTCQBIPIX the Company a clinical stage biopharmaceutical company is pleased to provide this update on Brilacidin as a novel inhibitor of Phosphodiesterase 4 PDE4 an important aspect of...